update on compounded semaglutide With B6 (Pyridoxine) FDA alerts health care providers,

Disclosures Yoshifumi Saisho received honoraria from Takeda Pharmaceutical Co

The GLP-1 receptor agonists segment is estimated to dominate the market due to their efficacy in improving glycemic control while promoting weight loss, making them a preferred option for managing type 2 diabetes

Latest kidney transplantation statistics: contrast of treatment for end-stage renal failure in Western countries and Japan

Pros and Cons of Breath Testing for Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth

New Indications : GLP-1 drugs are being tested for obesity-related conditions (NASH/non-alcoholic steatohepatitis, cardiovascular risk reduction, etc.)

FDA experts repeatedly stressed that adding the peptides to the section 503A bulk drug substances list would be a dangerous experiment, with physicians flying blind as far as dosing data and best prescription practices